Advertisement


Andrew D. Seidman, MD, and Meredith M. Regan, ScD, on Breast Cancer: Results From the TEXT and SOFT Trials

2018 ASCO Annual Meeting

Advertisement

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Meredith M. Regan, ScD, of Dana-Farber Cancer Institute, discuss study findings on absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, HER2-negative breast cancer (Abstract 503).



Related Videos

Bladder Cancer

Toni K. Choueiri, MD, and Jonathan E. Rosenberg, MD: Bladder Cancer Roundup

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss their perspectives on the top abstracts in bladder cancer presented at the 2018 ASCO Annual Meeting (Abstracts 4507, 4506, 4503, 4504).

Lung Cancer
Genomics/Genetics

Nathan A. Pennell, MD, PhD, on NSCLC: Lowering Genetic Testing Costs

Nathan A. Pennell, MD, PhD, of the Cleveland Clinic, discusses the economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in newly diagnosed metastatic non–small cell lung cancer (Abstract 9031).

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, and Elizabeth R. Plimack, MD, on RCC: Perspectives on KEYNOTE-427 and IMmotion151

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, offer their analysis of two key studies presented in renal cell cancer.

Kidney Cancer
Immunotherapy

David F. McDermott, MD, on RCC: Results of the KEYNOTE-427 Trial

David F. McDermott, MD, of Beth Israel Deaconess Medical Center, discusses study findings on pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (Abstract 4500).

Gynecologic Cancers

Martee L. Hensley, MD, on Leiomyosarcoma: Results From a GOG Treatment Trial

Martee L. Hensley, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings on adjuvant gemcitabine plus docetaxel followed by doxorubicin vs observation for uterus-limited, high-grade leiomyosarcoma (Abstract 5505).

Advertisement

Advertisement




Advertisement